Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
CNS Drugs. 2019 Jul;33(7):707-718. doi: 10.1007/s40263-019-00646-y.
Rotigotine (Neupro), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that delivers the drug over a 24-h period. In the EU, the rotigotine TP is approved as monotherapy for the treatment of early Parkinson's disease (PD) and as combination therapy with levodopa throughout the course of the disease. It is also approved for the treatment of PD in numerous other countries, including Australia, the USA, China and Japan. Rotigotine TP effectively improved motor and overall functioning in clinical trials in Caucasian and Asian patients with early PD (as monotherapy) or advanced PD (in combination with levodopa); treatment benefits appeared to be maintained in open-label extensions that followed patients for up to 6 years. Rotigotine TP was not consistently non-inferior to ropinirole and pramipexole in studies that included these oral non-ergolinic DAs as active comparators. Rotigotine TP variously improved some non-motor symptoms of PD, in particular sleep disturbances and health-related quality of life (HRQOL), based on findings from individual studies and/or a meta-analysis. Rotigotine TP was generally well tolerated, with an adverse event profile characterized by adverse events typical of dopaminergic stimulation and transdermal patch application. Available for more than a decade, rotigotine TP is a well-established, once-daily DA formulation for use in the short- and longer-term treatment of PD. It offers a convenient alternative when non-oral administration of medication is preferred and may be particularly useful in patients with gastrointestinal disturbances that reduce the suitability of oral medication.
罗替高汀（Neupro），一种非麦角类多巴胺激动剂（DA），通过透皮贴片（TP）每日给药一次，可在 24 小时内递送药物。在欧盟，罗替高汀 TP 被批准用于早期帕金森病（PD）的单药治疗，以及在疾病过程中与左旋多巴联合治疗。它还在包括澳大利亚、美国、中国和日本在内的许多其他国家被批准用于治疗 PD。罗替高汀 TP 在白种人和亚洲早期 PD（单药治疗）或晚期 PD（与左旋多巴联合治疗）患者的临床试验中有效改善了运动和整体功能；在后续患者长达 6 年的开放标签扩展研究中，治疗益处似乎得以维持。在包括这些口服非麦角类 DA 作为活性对照的研究中，罗替高汀 TP 并未始终非劣效于罗匹尼罗和普拉克索。基于个别研究和/或荟萃分析的结果，罗替高汀 TP 不同程度地改善了 PD 的一些非运动症状，特别是睡眠障碍和健康相关生活质量（HRQOL）。罗替高汀 TP 通常具有良好的耐受性，其不良事件谱的特征是与多巴胺能刺激和透皮贴片应用相关的不良事件。罗替高汀 TP 已经上市十多年，是一种成熟的、每日一次的 DA 制剂，用于 PD 的短期和长期治疗。当需要非口服给药时，它提供了一种方便的替代选择，对于胃肠道紊乱降低口服药物适用性的患者可能特别有用。
